NO20060149L - Farmasoytiske forbindelser av atorvastatin - Google Patents

Farmasoytiske forbindelser av atorvastatin

Info

Publication number
NO20060149L
NO20060149L NO20060149A NO20060149A NO20060149L NO 20060149 L NO20060149 L NO 20060149L NO 20060149 A NO20060149 A NO 20060149A NO 20060149 A NO20060149 A NO 20060149A NO 20060149 L NO20060149 L NO 20060149L
Authority
NO
Norway
Prior art keywords
atorvastatin
pharmaceutical composition
pharmaceutical compounds
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO20060149A
Other languages
English (en)
Inventor
Kenneth Craig Waterman
Paul Evan Luner
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20060149L publication Critical patent/NO20060149L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Tørrgranulert, farmasøytisk preparat omfattende atorvastatin eller et farmasøytisk akseptabelt salt derav så vel som et tørrgranulert farmasøytisk preparat omfattende atorvastatin eller et farmasøytisk akseptabelt salt derav i kombinasjon med minst ett annet aktivt medikament, fremgangsmåter for fremstilling av nevnte preparat, sett inneholdende slike preparat og en fremgangsmåte for behandling av hyperkolesterolemi og/eller hyperlipidemi, osteoporose, benign prostatisk hyperplasi (BPH), og Alzheimers sykdom ved anvendelse av en terapeutisk effektiv mengde av det farmasøytiske preparatet.
NO20060149A 2003-06-12 2006-01-10 Farmasoytiske forbindelser av atorvastatin NO20060149L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47791703P 2003-06-12 2003-06-12
PCT/IB2004/001859 WO2004110406A1 (en) 2003-06-12 2004-06-01 Pharmaceutical compositions of atorvastatin

Publications (1)

Publication Number Publication Date
NO20060149L true NO20060149L (no) 2006-03-06

Family

ID=33551780

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060149A NO20060149L (no) 2003-06-12 2006-01-10 Farmasoytiske forbindelser av atorvastatin

Country Status (15)

Country Link
EP (1) EP1635788A1 (no)
JP (1) JP2006527259A (no)
KR (1) KR100760112B1 (no)
CN (1) CN1805732A (no)
AR (1) AR044660A1 (no)
AU (1) AU2004246867A1 (no)
BR (1) BRPI0411354A (no)
CA (1) CA2465693A1 (no)
CO (1) CO5640071A2 (no)
MX (1) MXPA05012955A (no)
NO (1) NO20060149L (no)
RU (1) RU2325903C2 (no)
TW (1) TW200503689A (no)
WO (1) WO2004110406A1 (no)
ZA (1) ZA200508204B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004425A (es) * 2004-10-18 2007-06-07 Teva Pharma Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
PT2000137E (pt) 2006-03-29 2016-02-17 Kowa Co Agente redutor de triglicerídeos e agente melhorador de hiperinsulinismo
CN102976996B (zh) * 2009-05-27 2015-08-19 峡江和美药业有限公司 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
DK2512455T3 (en) 2009-12-18 2014-03-24 Frieslandcampina Nederland Holding B V Co-treated tablet adjuvant composition, its preparation and use
KR20120105035A (ko) * 2009-12-22 2012-09-24 노파르티스 아게 1ｈ-퀴나졸린-2,4-디온 ａｍｐａ 수용체 길항제를 포함하는 속방성 정제 형태의 제제 및 그의 제조
WO2011152803A1 (en) 2010-06-03 2011-12-08 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
CN104825449A (zh) * 2014-02-12 2015-08-12 天津药物研究院 含有阿托伐他汀钙和氨氯地平的复方组合物及其制备方法
JP6306690B2 (ja) * 2014-09-26 2018-04-04 株式会社フジクラ 光ファイバ
RU2591079C2 (ru) * 2014-12-10 2016-07-10 Александр Владимирович Диковский Фармацевтическая композиция статинов с пребиотиком для терапии гиперхолестеринемии и гиперлипидимии
KR20180016732A (ko) * 2015-06-10 2018-02-19 에보니크 룀 게엠베하 인간 응고 인자 단백질 및 락트산 중합체를 포함하는 분말의 제조 방법
CN106580908A (zh) * 2015-10-16 2017-04-26 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
WO2023025672A1 (en) 2021-08-25 2023-03-02 Basf Se Direct tableting auxiliary composition
CN114674944A (zh) * 2022-03-04 2022-06-28 苏州东瑞制药有限公司 一种检测苯磺酸氨氯地平与阿托伐他汀钙复方制剂有关物质的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003514798A (ja) * 1999-11-17 2003-04-22 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンカルシウムの多形
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
HUP0401234A2 (hu) * 2001-03-27 2004-11-29 Ranbaxy Laboratories Limited Pravastatin stabil gyógyászati kompozíciója és eljárás az előállítására
JP2003055217A (ja) * 2001-08-10 2003-02-26 Taiyo Yakuhin Kogyo Kk 医薬組成物
GB0121436D0 (en) * 2001-09-04 2001-10-24 Pfizer Ltd Biomodulated multiparticulate formulations
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
ES2310676T3 (es) * 2002-12-20 2009-01-16 Pfizer Products Inc. Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de hmg-coa reductasa.

Also Published As

Publication number Publication date
CN1805732A (zh) 2006-07-19
KR100760112B1 (ko) 2007-09-18
CO5640071A2 (es) 2006-05-31
WO2004110406A1 (en) 2004-12-23
KR20060025167A (ko) 2006-03-20
AU2004246867A1 (en) 2004-12-23
MXPA05012955A (es) 2006-02-13
RU2325903C2 (ru) 2008-06-10
CA2465693A1 (en) 2004-12-12
RU2005136743A (ru) 2006-07-27
ZA200508204B (en) 2007-03-28
EP1635788A1 (en) 2006-03-22
JP2006527259A (ja) 2006-11-30
AR044660A1 (es) 2005-09-21
BRPI0411354A (pt) 2006-07-11
TW200503689A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
NO20060149L (no) Farmasoytiske forbindelser av atorvastatin
NO20055185L (no) Farmasoytiske sammensetninger omfattende atorvastatin fremstilt uten granulering
NO20061640L (no) Hurtig opplosningspreparat av en kalsiumreseptiraktiv forbindelse
NO2007010I1 (no) Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
NO20060022L (no) Stabile sammensetninger av atorvastatin fremstilt ved vat granulering
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
LU92166I2 (fr) Glycopyrronium ou un de ses sels
ATE485290T1 (de) Platelet adp rezeptor inhibitoren
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE309999T1 (de) Blutplättchen-adp-rezeptor-inhibitoren
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
MA27809A1 (fr) Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogene-phosphorylase
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
WO2007078895A3 (en) Modified release formulations of tramadol and uses thereof
BRPI0518300A2 (pt) derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
NO20023486D0 (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
JP2005509503A5 (no)
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
SE0000303D0 (sv) Novel compounds
PL1806136T3 (pl) Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego
EA200401100A1 (ru) 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
NO20065196L (no) Terapeutisk kombinasjon for behandling av Alzheimers sykdom
WO2008079260A3 (en) Disintegration promoters in solid dose wet granulation formulations
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application